nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00953	0.118	CbGbCtD
Crizotinib—CYP3A5—Estradiol—osteoporosis	0.00943	0.117	CbGbCtD
Crizotinib—CYP3A4—Estropipate—osteoporosis	0.00886	0.109	CbGbCtD
Crizotinib—CYP3A4—Calcitriol—osteoporosis	0.00886	0.109	CbGbCtD
Crizotinib—SRC—periosteum—osteoporosis	0.00846	0.075	CbGeAlD
Crizotinib—CSF1R—periosteum—osteoporosis	0.0076	0.0673	CbGeAlD
Crizotinib—CYP3A4—Ergocalciferol—osteoporosis	0.00708	0.0875	CbGbCtD
Crizotinib—ABCB1—Conjugated Estrogens—osteoporosis	0.00699	0.0864	CbGbCtD
Crizotinib—ABCB1—Estradiol—osteoporosis	0.00614	0.0759	CbGbCtD
Crizotinib—CYP3A4—Raloxifene—osteoporosis	0.00591	0.073	CbGbCtD
Crizotinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00571	0.0705	CbGbCtD
Crizotinib—CYP3A4—Cholecalciferol—osteoporosis	0.00456	0.0564	CbGbCtD
Crizotinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00419	0.0518	CbGbCtD
Crizotinib—CYP3A4—Estradiol—osteoporosis	0.00368	0.0454	CbGbCtD
Crizotinib—PRKD3—uterus—osteoporosis	0.00296	0.0263	CbGeAlD
Crizotinib—MAPK7—uterus—osteoporosis	0.00274	0.0243	CbGeAlD
Crizotinib—FES—uterus—osteoporosis	0.00271	0.024	CbGeAlD
Crizotinib—MET—uterus—osteoporosis	0.00256	0.0227	CbGeAlD
Crizotinib—PRKD3—bone marrow—osteoporosis	0.00252	0.0223	CbGeAlD
Crizotinib—CDK7—uterus—osteoporosis	0.00248	0.022	CbGeAlD
Crizotinib—TXK—bone marrow—osteoporosis	0.00232	0.0206	CbGeAlD
Crizotinib—FES—bone marrow—osteoporosis	0.0023	0.0204	CbGeAlD
Crizotinib—DCLK1—uterus—osteoporosis	0.00225	0.0199	CbGeAlD
Crizotinib—TNK1—uterus—osteoporosis	0.00208	0.0184	CbGeAlD
Crizotinib—BMPR1B—uterus—osteoporosis	0.00206	0.0182	CbGeAlD
Crizotinib—TNK2—uterus—osteoporosis	0.00202	0.0179	CbGeAlD
Crizotinib—MAP4K2—uterus—osteoporosis	0.00199	0.0176	CbGeAlD
Crizotinib—STK3—uterus—osteoporosis	0.00196	0.0174	CbGeAlD
Crizotinib—TIE1—uterus—osteoporosis	0.00196	0.0174	CbGeAlD
Crizotinib—AURKA—uterus—osteoporosis	0.00191	0.0169	CbGeAlD
Crizotinib—PLK4—bone marrow—osteoporosis	0.0019	0.0168	CbGeAlD
Crizotinib—LIMK2—uterus—osteoporosis	0.0018	0.016	CbGeAlD
Crizotinib—ACVR1—uterus—osteoporosis	0.00178	0.0158	CbGeAlD
Crizotinib—MAP4K1—bone marrow—osteoporosis	0.00174	0.0154	CbGeAlD
Crizotinib—MAP4K2—bone marrow—osteoporosis	0.00169	0.0149	CbGeAlD
Crizotinib—AURKA—bone marrow—osteoporosis	0.00162	0.0144	CbGeAlD
Crizotinib—MERTK—bone marrow—osteoporosis	0.00156	0.0139	CbGeAlD
Crizotinib—EPHA4—uterus—osteoporosis	0.00156	0.0138	CbGeAlD
Crizotinib—MAP3K2—uterus—osteoporosis	0.00153	0.0135	CbGeAlD
Crizotinib—NUAK2—bone marrow—osteoporosis	0.00152	0.0135	CbGeAlD
Crizotinib—ACVR1—bone marrow—osteoporosis	0.00151	0.0134	CbGeAlD
Crizotinib—FLT3—bone marrow—osteoporosis	0.00151	0.0134	CbGeAlD
Crizotinib—PTK2—uterus—osteoporosis	0.0015	0.0132	CbGeAlD
Crizotinib—TYK2—uterus—osteoporosis	0.00149	0.0132	CbGeAlD
Crizotinib—IGF1R—Fulvestrant—Estradiol—osteoporosis	0.00144	0.167	CbGdCrCtD
Crizotinib—LCK—uterus—osteoporosis	0.00143	0.0127	CbGeAlD
Crizotinib—BMP2K—bone marrow—osteoporosis	0.00143	0.0126	CbGeAlD
Crizotinib—AXL—uterus—osteoporosis	0.00142	0.0126	CbGeAlD
Crizotinib—PTK2B—bone marrow—osteoporosis	0.00138	0.0122	CbGeAlD
Crizotinib—SLK—uterus—osteoporosis	0.00137	0.0121	CbGeAlD
Crizotinib—RIPK2—bone marrow—osteoporosis	0.00137	0.0121	CbGeAlD
Crizotinib—EPHB4—uterus—osteoporosis	0.00136	0.0121	CbGeAlD
Crizotinib—MAP4K5—uterus—osteoporosis	0.0013	0.0115	CbGeAlD
Crizotinib—TEK—uterus—osteoporosis	0.0013	0.0115	CbGeAlD
Crizotinib—MAP3K2—bone marrow—osteoporosis	0.0013	0.0115	CbGeAlD
Crizotinib—TBK1—bone marrow—osteoporosis	0.00127	0.0112	CbGeAlD
Crizotinib—TYK2—bone marrow—osteoporosis	0.00126	0.0112	CbGeAlD
Crizotinib—IRAK1—bone marrow—osteoporosis	0.00124	0.011	CbGeAlD
Crizotinib—RPS6KB1—bone marrow—osteoporosis	0.00122	0.0108	CbGeAlD
Crizotinib—LCK—bone marrow—osteoporosis	0.00121	0.0108	CbGeAlD
Crizotinib—FGR—bone marrow—osteoporosis	0.00121	0.0108	CbGeAlD
Crizotinib—TESK1—Estradiol—Estropipate—osteoporosis	0.0012	0.139	CbGdCrCtD
Crizotinib—YES1—uterus—osteoporosis	0.0012	0.0107	CbGeAlD
Crizotinib—STK10—uterus—osteoporosis	0.00119	0.0106	CbGeAlD
Crizotinib—TAOK3—uterus—osteoporosis	0.00119	0.0105	CbGeAlD
Crizotinib—SLK—bone marrow—osteoporosis	0.00116	0.0103	CbGeAlD
Crizotinib—EPHB4—bone marrow—osteoporosis	0.00116	0.0102	CbGeAlD
Crizotinib—JAK2—bone marrow—osteoporosis	0.00115	0.0102	CbGeAlD
Crizotinib—MAP3K3—bone marrow—osteoporosis	0.00111	0.00979	CbGeAlD
Crizotinib—MAP4K5—bone marrow—osteoporosis	0.00111	0.00979	CbGeAlD
Crizotinib—CSF1R—uterus—osteoporosis	0.00104	0.0092	CbGeAlD
Crizotinib—YES1—bone marrow—osteoporosis	0.00102	0.00904	CbGeAlD
Crizotinib—STK10—bone marrow—osteoporosis	0.00101	0.00896	CbGeAlD
Crizotinib—TAOK3—bone marrow—osteoporosis	0.00101	0.00893	CbGeAlD
Crizotinib—TESK1—Estradiol—Conjugated Estrogens—osteoporosis	0.000912	0.106	CbGdCrCtD
Crizotinib—AURKA—Calcipotriol—Calcitriol—osteoporosis	0.000896	0.104	CbGdCrCtD
Crizotinib—AURKA—Calcipotriol—Ergocalciferol—osteoporosis	0.000896	0.104	CbGdCrCtD
Crizotinib—CSF1R—bone marrow—osteoporosis	0.000882	0.00781	CbGeAlD
Crizotinib—ABL1—uterus—osteoporosis	0.000821	0.00728	CbGeAlD
Crizotinib—TESK1—Estradiol—Ethinyl Estradiol—osteoporosis	0.000767	0.0887	CbGdCrCtD
Crizotinib—AURKA—Calcipotriol—Cholecalciferol—osteoporosis	0.000762	0.0881	CbGdCrCtD
Crizotinib—PLK4—Fulvestrant—Estradiol—osteoporosis	0.000757	0.0875	CbGdCrCtD
Crizotinib—ABL1—bone marrow—osteoporosis	0.000697	0.00617	CbGeAlD
Crizotinib—Cardiac disorder—Pamidronate—osteoporosis	0.00068	0.00207	CcSEcCtD
Crizotinib—Nervous system disorder—Estropipate—osteoporosis	0.00068	0.00207	CcSEcCtD
Crizotinib—Hepatobiliary disease—Conjugated Estrogens—osteoporosis	0.000679	0.00207	CcSEcCtD
Crizotinib—Infection—Alendronate—osteoporosis	0.000678	0.00207	CcSEcCtD
Crizotinib—Skin disorder—Estropipate—osteoporosis	0.000673	0.00205	CcSEcCtD
Crizotinib—Malnutrition—Risedronate—osteoporosis	0.000671	0.00204	CcSEcCtD
Crizotinib—Infection—Raloxifene—osteoporosis	0.000667	0.00203	CcSEcCtD
Crizotinib—Hypoaesthesia—Zoledronate—osteoporosis	0.000666	0.00203	CcSEcCtD
Crizotinib—Urinary tract disorder—Zoledronate—osteoporosis	0.000661	0.00201	CcSEcCtD
Crizotinib—Mediastinal disorder—Pamidronate—osteoporosis	0.000661	0.00201	CcSEcCtD
Crizotinib—Shock—Raloxifene—osteoporosis	0.000661	0.00201	CcSEcCtD
Crizotinib—Infection—Ibandronate—osteoporosis	0.00066	0.00201	CcSEcCtD
Crizotinib—Oedema peripheral—Zoledronate—osteoporosis	0.00066	0.00201	CcSEcCtD
Crizotinib—Nervous system disorder—Raloxifene—osteoporosis	0.000659	0.00201	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Estradiol—osteoporosis	0.000658	0.002	CcSEcCtD
Crizotinib—Urethral disorder—Zoledronate—osteoporosis	0.000656	0.002	CcSEcCtD
Crizotinib—Shock—Ibandronate—osteoporosis	0.000654	0.00199	CcSEcCtD
Crizotinib—Skin disorder—Raloxifene—osteoporosis	0.000652	0.00199	CcSEcCtD
Crizotinib—Nervous system disorder—Ibandronate—osteoporosis	0.000652	0.00198	CcSEcCtD
Crizotinib—Skin disorder—Ibandronate—osteoporosis	0.000646	0.00197	CcSEcCtD
Crizotinib—Hypoaesthesia—Conjugated Estrogens—osteoporosis	0.000641	0.00195	CcSEcCtD
Crizotinib—Nausea—Ergocalciferol—osteoporosis	0.00064	0.00195	CcSEcCtD
Crizotinib—Malnutrition—Pamidronate—osteoporosis	0.000638	0.00194	CcSEcCtD
Crizotinib—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.000635	0.00193	CcSEcCtD
Crizotinib—Skin disorder—Calcitriol—osteoporosis	0.000632	0.00192	CcSEcCtD
Crizotinib—Eye disorder—Zoledronate—osteoporosis	0.000626	0.00191	CcSEcCtD
Crizotinib—Dysgeusia—Pamidronate—osteoporosis	0.000625	0.0019	CcSEcCtD
Crizotinib—Paraesthesia—Estropipate—osteoporosis	0.000622	0.0019	CcSEcCtD
Crizotinib—Cardiac disorder—Zoledronate—osteoporosis	0.000621	0.00189	CcSEcCtD
Crizotinib—Visual impairment—Conjugated Estrogens—osteoporosis	0.000621	0.00189	CcSEcCtD
Crizotinib—Anaemia—Risedronate—osteoporosis	0.00062	0.00189	CcSEcCtD
Crizotinib—Dyspepsia—Estropipate—osteoporosis	0.00061	0.00186	CcSEcCtD
Crizotinib—Mediastinal disorder—Zoledronate—osteoporosis	0.000603	0.00184	CcSEcCtD
Crizotinib—Eye disorder—Conjugated Estrogens—osteoporosis	0.000603	0.00183	CcSEcCtD
Crizotinib—Syncope—Risedronate—osteoporosis	0.000602	0.00183	CcSEcCtD
Crizotinib—Dyspepsia—Alendronate—osteoporosis	0.000601	0.00183	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Estradiol—osteoporosis	0.000599	0.00182	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Estropipate—osteoporosis	0.000598	0.00182	CcSEcCtD
Crizotinib—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000598	0.00182	CcSEcCtD
Crizotinib—Arrhythmia—Zoledronate—osteoporosis	0.000598	0.00182	CcSEcCtD
Crizotinib—Fatigue—Estropipate—osteoporosis	0.000598	0.00182	CcSEcCtD
Crizotinib—Paraesthesia—Ibandronate—osteoporosis	0.000597	0.00182	CcSEcCtD
Crizotinib—Constipation—Estropipate—osteoporosis	0.000593	0.0018	CcSEcCtD
Crizotinib—AURKA—Fulvestrant—Estradiol—osteoporosis	0.000592	0.0685	CbGdCrCtD
Crizotinib—Dyspepsia—Raloxifene—osteoporosis	0.000591	0.0018	CcSEcCtD
Crizotinib—Loss of consciousness—Risedronate—osteoporosis	0.00059	0.0018	CcSEcCtD
Crizotinib—Anaemia—Pamidronate—osteoporosis	0.00059	0.0018	CcSEcCtD
Crizotinib—Dyspepsia—Ibandronate—osteoporosis	0.000585	0.00178	CcSEcCtD
Crizotinib—Constipation—Alendronate—osteoporosis	0.000584	0.00178	CcSEcCtD
Crizotinib—Weight decreased—Estradiol—osteoporosis	0.000583	0.00178	CcSEcCtD
Crizotinib—Malnutrition—Zoledronate—osteoporosis	0.000583	0.00177	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000582	0.00177	CcSEcCtD
Crizotinib—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000581	0.00177	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Raloxifene—osteoporosis	0.00058	0.00177	CcSEcCtD
Crizotinib—Pneumonia—Estradiol—osteoporosis	0.000578	0.00176	CcSEcCtD
Crizotinib—Decreased appetite—Ibandronate—osteoporosis	0.000578	0.00176	CcSEcCtD
Crizotinib—Arrhythmia—Conjugated Estrogens—osteoporosis	0.000576	0.00175	CcSEcCtD
Crizotinib—Infestation—Estradiol—osteoporosis	0.000575	0.00175	CcSEcCtD
Crizotinib—Infestation NOS—Estradiol—osteoporosis	0.000575	0.00175	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000574	0.00175	CcSEcCtD
Crizotinib—Fatigue—Ibandronate—osteoporosis	0.000573	0.00175	CcSEcCtD
Crizotinib—Syncope—Pamidronate—osteoporosis	0.000572	0.00174	CcSEcCtD
Crizotinib—Leukopenia—Pamidronate—osteoporosis	0.000571	0.00174	CcSEcCtD
Crizotinib—Dysgeusia—Zoledronate—osteoporosis	0.000571	0.00174	CcSEcCtD
Crizotinib—Constipation—Ibandronate—osteoporosis	0.000568	0.00173	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000568	0.00173	CcSEcCtD
Crizotinib—Decreased appetite—Calcitriol—osteoporosis	0.000566	0.00172	CcSEcCtD
Crizotinib—Neuropathy peripheral—Estradiol—osteoporosis	0.000563	0.00172	CcSEcCtD
Crizotinib—Oedema—Ethinyl Estradiol—osteoporosis	0.000562	0.00171	CcSEcCtD
Crizotinib—Malnutrition—Conjugated Estrogens—osteoporosis	0.000561	0.00171	CcSEcCtD
Crizotinib—Loss of consciousness—Pamidronate—osteoporosis	0.000561	0.00171	CcSEcCtD
Crizotinib—Infection—Ethinyl Estradiol—osteoporosis	0.000558	0.0017	CcSEcCtD
Crizotinib—Constipation—Calcitriol—osteoporosis	0.000556	0.00169	CcSEcCtD
Crizotinib—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000551	0.00168	CcSEcCtD
Crizotinib—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00055	0.00167	CcSEcCtD
Crizotinib—Vision blurred—Zoledronate—osteoporosis	0.000549	0.00167	CcSEcCtD
Crizotinib—Diarrhoea—Etidronic acid—osteoporosis	0.000548	0.00167	CcSEcCtD
Crizotinib—Body temperature increased—Estropipate—osteoporosis	0.000548	0.00167	CcSEcCtD
Crizotinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000546	0.00166	CcSEcCtD
Crizotinib—Infection—Risedronate—osteoporosis	0.000544	0.00166	CcSEcCtD
Crizotinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000544	0.00166	CcSEcCtD
Crizotinib—Body temperature increased—Alendronate—osteoporosis	0.00054	0.00164	CcSEcCtD
Crizotinib—Shock—Risedronate—osteoporosis	0.000539	0.00164	CcSEcCtD
Crizotinib—Anaemia—Zoledronate—osteoporosis	0.000539	0.00164	CcSEcCtD
Crizotinib—Nervous system disorder—Risedronate—osteoporosis	0.000537	0.00164	CcSEcCtD
Crizotinib—Skin disorder—Risedronate—osteoporosis	0.000532	0.00162	CcSEcCtD
Crizotinib—Body temperature increased—Raloxifene—osteoporosis	0.000531	0.00162	CcSEcCtD
Crizotinib—Vision blurred—Conjugated Estrogens—osteoporosis	0.000529	0.00161	CcSEcCtD
Crizotinib—Body temperature increased—Ibandronate—osteoporosis	0.000526	0.0016	CcSEcCtD
Crizotinib—Syncope—Zoledronate—osteoporosis	0.000523	0.00159	CcSEcCtD
Crizotinib—Leukopenia—Zoledronate—osteoporosis	0.000522	0.00159	CcSEcCtD
Crizotinib—Oedema—Pamidronate—osteoporosis	0.000521	0.00159	CcSEcCtD
Crizotinib—Infection—Pamidronate—osteoporosis	0.000517	0.00158	CcSEcCtD
Crizotinib—Body temperature increased—Calcitriol—osteoporosis	0.000514	0.00157	CcSEcCtD
Crizotinib—Hypoaesthesia—Estradiol—osteoporosis	0.000513	0.00156	CcSEcCtD
Crizotinib—Shock—Pamidronate—osteoporosis	0.000512	0.00156	CcSEcCtD
Crizotinib—Loss of consciousness—Zoledronate—osteoporosis	0.000512	0.00156	CcSEcCtD
Crizotinib—Nervous system disorder—Pamidronate—osteoporosis	0.000511	0.00156	CcSEcCtD
Crizotinib—Urinary tract disorder—Estradiol—osteoporosis	0.00051	0.00155	CcSEcCtD
Crizotinib—Vomiting—Etidronic acid—osteoporosis	0.000509	0.00155	CcSEcCtD
Crizotinib—Oedema peripheral—Estradiol—osteoporosis	0.000508	0.00155	CcSEcCtD
Crizotinib—Urethral disorder—Estradiol—osteoporosis	0.000506	0.00154	CcSEcCtD
Crizotinib—Rash—Etidronic acid—osteoporosis	0.000505	0.00154	CcSEcCtD
Crizotinib—Dermatitis—Etidronic acid—osteoporosis	0.000505	0.00154	CcSEcCtD
Crizotinib—Syncope—Conjugated Estrogens—osteoporosis	0.000503	0.00153	CcSEcCtD
Crizotinib—Asthenia—Estropipate—osteoporosis	0.000497	0.00151	CcSEcCtD
Crizotinib—Visual impairment—Estradiol—osteoporosis	0.000497	0.00151	CcSEcCtD
Crizotinib—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000493	0.0015	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000493	0.0015	CcSEcCtD
Crizotinib—Paraesthesia—Risedronate—osteoporosis	0.000492	0.0015	CcSEcCtD
Crizotinib—Asthenia—Alendronate—osteoporosis	0.00049	0.00149	CcSEcCtD
Crizotinib—Dyspnoea—Risedronate—osteoporosis	0.000488	0.00149	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000485	0.00148	CcSEcCtD
Crizotinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000484	0.00148	CcSEcCtD
Crizotinib—Dyspepsia—Risedronate—osteoporosis	0.000482	0.00147	CcSEcCtD
Crizotinib—Eye disorder—Estradiol—osteoporosis	0.000482	0.00147	CcSEcCtD
Crizotinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000481	0.00146	CcSEcCtD
Crizotinib—Cardiac disorder—Estradiol—osteoporosis	0.000479	0.00146	CcSEcCtD
Crizotinib—Asthenia—Ibandronate—osteoporosis	0.000477	0.00145	CcSEcCtD
Crizotinib—Nausea—Etidronic acid—osteoporosis	0.000476	0.00145	CcSEcCtD
Crizotinib—Oedema—Zoledronate—osteoporosis	0.000476	0.00145	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000475	0.00144	CcSEcCtD
Crizotinib—Diarrhoea—Estropipate—osteoporosis	0.000474	0.00144	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000473	0.00144	CcSEcCtD
Crizotinib—Infection—Zoledronate—osteoporosis	0.000473	0.00144	CcSEcCtD
Crizotinib—Fatigue—Risedronate—osteoporosis	0.000472	0.00144	CcSEcCtD
Crizotinib—Constipation—Risedronate—osteoporosis	0.000468	0.00143	CcSEcCtD
Crizotinib—Shock—Zoledronate—osteoporosis	0.000468	0.00143	CcSEcCtD
Crizotinib—Paraesthesia—Pamidronate—osteoporosis	0.000468	0.00142	CcSEcCtD
Crizotinib—Diarrhoea—Alendronate—osteoporosis	0.000467	0.00142	CcSEcCtD
Crizotinib—Asthenia—Calcitriol—osteoporosis	0.000467	0.00142	CcSEcCtD
Crizotinib—Nervous system disorder—Zoledronate—osteoporosis	0.000467	0.00142	CcSEcCtD
Crizotinib—Mediastinal disorder—Estradiol—osteoporosis	0.000465	0.00142	CcSEcCtD
Crizotinib—Dyspnoea—Pamidronate—osteoporosis	0.000464	0.00141	CcSEcCtD
Crizotinib—Skin disorder—Zoledronate—osteoporosis	0.000462	0.00141	CcSEcCtD
Crizotinib—Diarrhoea—Raloxifene—osteoporosis	0.000459	0.0014	CcSEcCtD
Crizotinib—Dyspepsia—Pamidronate—osteoporosis	0.000458	0.0014	CcSEcCtD
Crizotinib—Dizziness—Estropipate—osteoporosis	0.000458	0.0014	CcSEcCtD
Crizotinib—Oedema—Conjugated Estrogens—osteoporosis	0.000458	0.00139	CcSEcCtD
Crizotinib—Infection—Conjugated Estrogens—osteoporosis	0.000455	0.00139	CcSEcCtD
Crizotinib—Diarrhoea—Ibandronate—osteoporosis	0.000455	0.00138	CcSEcCtD
Crizotinib—Decreased appetite—Pamidronate—osteoporosis	0.000453	0.00138	CcSEcCtD
Crizotinib—Dizziness—Alendronate—osteoporosis	0.000452	0.00137	CcSEcCtD
Crizotinib—Shock—Conjugated Estrogens—osteoporosis	0.000451	0.00137	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00045	0.00137	CcSEcCtD
Crizotinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000449	0.00137	CcSEcCtD
Crizotinib—Malnutrition—Estradiol—osteoporosis	0.000449	0.00137	CcSEcCtD
Crizotinib—Fatigue—Pamidronate—osteoporosis	0.000449	0.00137	CcSEcCtD
Crizotinib—Constipation—Pamidronate—osteoporosis	0.000445	0.00136	CcSEcCtD
Crizotinib—Diarrhoea—Calcitriol—osteoporosis	0.000445	0.00136	CcSEcCtD
Crizotinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000445	0.00135	CcSEcCtD
Crizotinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000444	0.00135	CcSEcCtD
Crizotinib—Dizziness—Raloxifene—osteoporosis	0.000444	0.00135	CcSEcCtD
Crizotinib—Vomiting—Estropipate—osteoporosis	0.000441	0.00134	CcSEcCtD
Crizotinib—Dysgeusia—Estradiol—osteoporosis	0.00044	0.00134	CcSEcCtD
Crizotinib—Dizziness—Ibandronate—osteoporosis	0.00044	0.00134	CcSEcCtD
Crizotinib—Rash—Estropipate—osteoporosis	0.000437	0.00133	CcSEcCtD
Crizotinib—Dermatitis—Estropipate—osteoporosis	0.000437	0.00133	CcSEcCtD
Crizotinib—Vomiting—Alendronate—osteoporosis	0.000434	0.00132	CcSEcCtD
Crizotinib—Body temperature increased—Risedronate—osteoporosis	0.000433	0.00132	CcSEcCtD
Crizotinib—Rash—Alendronate—osteoporosis	0.000431	0.00131	CcSEcCtD
Crizotinib—Dermatitis—Alendronate—osteoporosis	0.00043	0.00131	CcSEcCtD
Crizotinib—Paraesthesia—Zoledronate—osteoporosis	0.000427	0.0013	CcSEcCtD
Crizotinib—Vomiting—Raloxifene—osteoporosis	0.000427	0.0013	CcSEcCtD
Crizotinib—Dyspnoea—Zoledronate—osteoporosis	0.000424	0.00129	CcSEcCtD
Crizotinib—Rash—Raloxifene—osteoporosis	0.000423	0.00129	CcSEcCtD
Crizotinib—Dermatitis—Raloxifene—osteoporosis	0.000423	0.00129	CcSEcCtD
Crizotinib—Vomiting—Ibandronate—osteoporosis	0.000423	0.00129	CcSEcCtD
Crizotinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.00042	0.0486	CbGdCrCtD
Crizotinib—Rash—Ibandronate—osteoporosis	0.000419	0.00128	CcSEcCtD
Crizotinib—Dermatitis—Ibandronate—osteoporosis	0.000419	0.00128	CcSEcCtD
Crizotinib—Dyspepsia—Zoledronate—osteoporosis	0.000419	0.00127	CcSEcCtD
Crizotinib—Vomiting—Calcitriol—osteoporosis	0.000414	0.00126	CcSEcCtD
Crizotinib—Decreased appetite—Zoledronate—osteoporosis	0.000414	0.00126	CcSEcCtD
Crizotinib—Nausea—Estropipate—osteoporosis	0.000412	0.00125	CcSEcCtD
Crizotinib—Body temperature increased—Pamidronate—osteoporosis	0.000412	0.00125	CcSEcCtD
Crizotinib—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000411	0.00125	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000411	0.00125	CcSEcCtD
Crizotinib—Rash—Calcitriol—osteoporosis	0.00041	0.00125	CcSEcCtD
Crizotinib—Fatigue—Zoledronate—osteoporosis	0.00041	0.00125	CcSEcCtD
Crizotinib—Dermatitis—Calcitriol—osteoporosis	0.00041	0.00125	CcSEcCtD
Crizotinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000408	0.00124	CcSEcCtD
Crizotinib—Constipation—Zoledronate—osteoporosis	0.000407	0.00124	CcSEcCtD
Crizotinib—Nausea—Alendronate—osteoporosis	0.000406	0.00123	CcSEcCtD
Crizotinib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000403	0.00123	CcSEcCtD
Crizotinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000403	0.00123	CcSEcCtD
Crizotinib—Syncope—Estradiol—osteoporosis	0.000403	0.00123	CcSEcCtD
Crizotinib—Nausea—Raloxifene—osteoporosis	0.000399	0.00121	CcSEcCtD
Crizotinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000398	0.00121	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000395	0.0012	CcSEcCtD
Crizotinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000395	0.0012	CcSEcCtD
Crizotinib—Nausea—Ibandronate—osteoporosis	0.000395	0.0012	CcSEcCtD
Crizotinib—Loss of consciousness—Estradiol—osteoporosis	0.000395	0.0012	CcSEcCtD
Crizotinib—Asthenia—Risedronate—osteoporosis	0.000393	0.0012	CcSEcCtD
Crizotinib—Constipation—Conjugated Estrogens—osteoporosis	0.000392	0.00119	CcSEcCtD
Crizotinib—Nausea—Calcitriol—osteoporosis	0.000387	0.00118	CcSEcCtD
Crizotinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000384	0.00117	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00038	0.00116	CcSEcCtD
Crizotinib—Body temperature increased—Zoledronate—osteoporosis	0.000376	0.00115	CcSEcCtD
Crizotinib—Diarrhoea—Risedronate—osteoporosis	0.000375	0.00114	CcSEcCtD
Crizotinib—Asthenia—Pamidronate—osteoporosis	0.000374	0.00114	CcSEcCtD
Crizotinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000372	0.00113	CcSEcCtD
Crizotinib—Oedema—Estradiol—osteoporosis	0.000367	0.00112	CcSEcCtD
Crizotinib—Infection—Estradiol—osteoporosis	0.000364	0.00111	CcSEcCtD
Crizotinib—Dizziness—Risedronate—osteoporosis	0.000362	0.0011	CcSEcCtD
Crizotinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000362	0.0011	CcSEcCtD
Crizotinib—Shock—Estradiol—osteoporosis	0.000361	0.0011	CcSEcCtD
Crizotinib—Nervous system disorder—Estradiol—osteoporosis	0.00036	0.00109	CcSEcCtD
Crizotinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000357	0.00109	CcSEcCtD
Crizotinib—Diarrhoea—Pamidronate—osteoporosis	0.000356	0.00108	CcSEcCtD
Crizotinib—Skin disorder—Estradiol—osteoporosis	0.000356	0.00108	CcSEcCtD
Crizotinib—Rash—Ethinyl Estradiol—osteoporosis	0.000354	0.00108	CcSEcCtD
Crizotinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000354	0.00108	CcSEcCtD
Crizotinib—Vomiting—Risedronate—osteoporosis	0.000348	0.00106	CcSEcCtD
Crizotinib—Rash—Risedronate—osteoporosis	0.000345	0.00105	CcSEcCtD
Crizotinib—Dermatitis—Risedronate—osteoporosis	0.000345	0.00105	CcSEcCtD
Crizotinib—Dizziness—Pamidronate—osteoporosis	0.000344	0.00105	CcSEcCtD
Crizotinib—Asthenia—Zoledronate—osteoporosis	0.000341	0.00104	CcSEcCtD
Crizotinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000334	0.00102	CcSEcCtD
Crizotinib—Vomiting—Pamidronate—osteoporosis	0.000331	0.00101	CcSEcCtD
Crizotinib—Paraesthesia—Estradiol—osteoporosis	0.000329	0.001	CcSEcCtD
Crizotinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000329	0.001	CcSEcCtD
Crizotinib—Rash—Pamidronate—osteoporosis	0.000328	0.001	CcSEcCtD
Crizotinib—Dermatitis—Pamidronate—osteoporosis	0.000328	0.000999	CcSEcCtD
Crizotinib—Dyspnoea—Estradiol—osteoporosis	0.000327	0.000995	CcSEcCtD
Crizotinib—Diarrhoea—Zoledronate—osteoporosis	0.000325	0.000991	CcSEcCtD
Crizotinib—Nausea—Risedronate—osteoporosis	0.000325	0.000991	CcSEcCtD
Crizotinib—Dyspepsia—Estradiol—osteoporosis	0.000323	0.000983	CcSEcCtD
Crizotinib—Decreased appetite—Estradiol—osteoporosis	0.000319	0.00097	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000316	0.000964	CcSEcCtD
Crizotinib—Fatigue—Estradiol—osteoporosis	0.000316	0.000962	CcSEcCtD
Crizotinib—Dizziness—Zoledronate—osteoporosis	0.000315	0.000958	CcSEcCtD
Crizotinib—Constipation—Estradiol—osteoporosis	0.000313	0.000955	CcSEcCtD
Crizotinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000313	0.000954	CcSEcCtD
Crizotinib—Nausea—Pamidronate—osteoporosis	0.000309	0.000942	CcSEcCtD
Crizotinib—Dizziness—Conjugated Estrogens—osteoporosis	0.000303	0.000922	CcSEcCtD
Crizotinib—Vomiting—Zoledronate—osteoporosis	0.000302	0.000921	CcSEcCtD
Crizotinib—Rash—Zoledronate—osteoporosis	0.0003	0.000913	CcSEcCtD
Crizotinib—Dermatitis—Zoledronate—osteoporosis	0.0003	0.000912	CcSEcCtD
Crizotinib—Vomiting—Conjugated Estrogens—osteoporosis	0.000291	0.000887	CcSEcCtD
Crizotinib—Body temperature increased—Estradiol—osteoporosis	0.00029	0.000882	CcSEcCtD
Crizotinib—Rash—Conjugated Estrogens—osteoporosis	0.000289	0.000879	CcSEcCtD
Crizotinib—Dermatitis—Conjugated Estrogens—osteoporosis	0.000289	0.000879	CcSEcCtD
Crizotinib—Nausea—Zoledronate—osteoporosis	0.000283	0.00086	CcSEcCtD
Crizotinib—Nausea—Conjugated Estrogens—osteoporosis	0.000272	0.000828	CcSEcCtD
Crizotinib—Asthenia—Estradiol—osteoporosis	0.000263	0.000801	CcSEcCtD
Crizotinib—ABCB1—uterus—osteoporosis	0.000255	0.00226	CbGeAlD
Crizotinib—Diarrhoea—Estradiol—osteoporosis	0.000251	0.000764	CcSEcCtD
Crizotinib—Dizziness—Estradiol—osteoporosis	0.000242	0.000738	CcSEcCtD
Crizotinib—Vomiting—Estradiol—osteoporosis	0.000233	0.00071	CcSEcCtD
Crizotinib—Rash—Estradiol—osteoporosis	0.000231	0.000704	CcSEcCtD
Crizotinib—Dermatitis—Estradiol—osteoporosis	0.000231	0.000703	CcSEcCtD
Crizotinib—Nausea—Estradiol—osteoporosis	0.000218	0.000663	CcSEcCtD
Crizotinib—ABCB1—bone marrow—osteoporosis	0.000217	0.00192	CbGeAlD
Crizotinib—ABCB1—Metabolism—ACP5—osteoporosis	6.99e-06	1.49e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTHLH—osteoporosis	6.96e-06	1.48e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BMP2—osteoporosis	6.96e-06	1.48e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IGF1—osteoporosis	6.95e-06	1.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—IL6—osteoporosis	6.94e-06	1.48e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CALCA—osteoporosis	6.93e-06	1.48e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—LEP—osteoporosis	6.9e-06	1.47e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL1B—osteoporosis	6.9e-06	1.47e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MYC—osteoporosis	6.87e-06	1.47e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TGFB1—osteoporosis	6.86e-06	1.46e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—IL6—osteoporosis	6.84e-06	1.46e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6R—osteoporosis	6.84e-06	1.46e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6R—osteoporosis	6.83e-06	1.46e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGB—osteoporosis	6.82e-06	1.45e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL1B—osteoporosis	6.81e-06	1.45e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—AGER—osteoporosis	6.77e-06	1.44e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ADCY5—osteoporosis	6.75e-06	1.44e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IGF1—osteoporosis	6.74e-06	1.44e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MYC—osteoporosis	6.73e-06	1.43e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TGFB1—osteoporosis	6.71e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—osteoporosis	6.7e-06	1.43e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IRS2—osteoporosis	6.69e-06	1.43e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ATIC—osteoporosis	6.69e-06	1.43e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PNP—osteoporosis	6.69e-06	1.43e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—ESR1—osteoporosis	6.68e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6R—osteoporosis	6.67e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRS2—osteoporosis	6.67e-06	1.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IRS1—osteoporosis	6.65e-06	1.42e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6R—osteoporosis	6.64e-06	1.42e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—MYC—osteoporosis	6.63e-06	1.41e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—TGFB1—osteoporosis	6.61e-06	1.41e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—ESR1—osteoporosis	6.59e-06	1.4e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.59e-06	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PSMA5—osteoporosis	6.58e-06	1.4e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PSMA2—osteoporosis	6.58e-06	1.4e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	6.57e-06	1.4e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—LEP—osteoporosis	6.55e-06	1.4e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—osteoporosis	6.54e-06	1.39e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TPI1—osteoporosis	6.5e-06	1.39e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IRS2—osteoporosis	6.49e-06	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—osteoporosis	6.49e-06	1.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—osteoporosis	6.49e-06	1.38e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—osteoporosis	6.47e-06	1.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL1B—osteoporosis	6.45e-06	1.38e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—osteoporosis	6.39e-06	1.36e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—LEP—osteoporosis	6.36e-06	1.35e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—osteoporosis	6.32e-06	1.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—osteoporosis	6.3e-06	1.34e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KL—osteoporosis	6.29e-06	1.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL1B—osteoporosis	6.27e-06	1.34e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ENO1—osteoporosis	6.26e-06	1.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—ESR1—osteoporosis	6.25e-06	1.33e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IRS1—osteoporosis	6.24e-06	1.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6R—osteoporosis	6.24e-06	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—ADCY5—osteoporosis	6.23e-06	1.33e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PSMA2—osteoporosis	6.17e-06	1.32e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PSMA5—osteoporosis	6.17e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TGFB1—osteoporosis	6.16e-06	1.31e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IRS1—osteoporosis	6.16e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IRS2—osteoporosis	6.16e-06	1.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IRS1—osteoporosis	6.14e-06	1.31e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CALCA—osteoporosis	6.13e-06	1.31e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—osteoporosis	6.13e-06	1.31e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—P4HB—osteoporosis	6.11e-06	1.3e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—ESR1—osteoporosis	6.07e-06	1.29e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—POMC—osteoporosis	6.01e-06	1.28e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ADCY5—osteoporosis	6.01e-06	1.28e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GAPDH—osteoporosis	6e-06	1.28e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—POMC—osteoporosis	5.93e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRS2—osteoporosis	5.9e-06	1.26e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—osteoporosis	5.87e-06	1.25e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6R—osteoporosis	5.87e-06	1.25e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—RAP1A—osteoporosis	5.84e-06	1.25e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IRS1—osteoporosis	5.84e-06	1.25e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IRS1—osteoporosis	5.82e-06	1.24e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SPP1—osteoporosis	5.82e-06	1.24e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6R—osteoporosis	5.78e-06	1.23e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IGF1—osteoporosis	5.78e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—osteoporosis	5.78e-06	1.23e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—osteoporosis	5.78e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6R—osteoporosis	5.76e-06	1.23e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—osteoporosis	5.75e-06	1.23e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—osteoporosis	5.73e-06	1.22e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—osteoporosis	5.71e-06	1.22e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IGF1—osteoporosis	5.7e-06	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CA2—osteoporosis	5.69e-06	1.21e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—OXCT1—osteoporosis	5.69e-06	1.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IRS1—osteoporosis	5.67e-06	1.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ADCY5—osteoporosis	5.63e-06	1.2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—POMC—osteoporosis	5.62e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KL—osteoporosis	5.57e-06	1.19e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TGFB1—osteoporosis	5.56e-06	1.19e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MGLL—osteoporosis	5.54e-06	1.18e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6R—osteoporosis	5.49e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6R—osteoporosis	5.47e-06	1.17e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—POMC—osteoporosis	5.46e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TGFB1—osteoporosis	5.46e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—IRS2—osteoporosis	5.45e-06	1.16e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SPP1—osteoporosis	5.44e-06	1.16e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IGF1—osteoporosis	5.41e-06	1.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—osteoporosis	5.41e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IRS1—osteoporosis	5.37e-06	1.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6R—osteoporosis	5.33e-06	1.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IRS2—osteoporosis	5.26e-06	1.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IGF1—osteoporosis	5.25e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—osteoporosis	5.19e-06	1.11e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—osteoporosis	5.17e-06	1.1e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IRS1—osteoporosis	5.15e-06	1.1e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—osteoporosis	5.15e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—LEP—osteoporosis	5.15e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—osteoporosis	5.1e-06	1.09e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—osteoporosis	5.08e-06	1.08e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—osteoporosis	5.08e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL1B—osteoporosis	5.07e-06	1.08e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—osteoporosis	5.06e-06	1.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL1B—osteoporosis	5.05e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6R—osteoporosis	5.05e-06	1.08e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	5.01e-06	1.07e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—osteoporosis	4.98e-06	1.06e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—osteoporosis	4.97e-06	1.06e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TGFB1—osteoporosis	4.96e-06	1.06e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—osteoporosis	4.95e-06	1.06e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—osteoporosis	4.94e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ADCY5—osteoporosis	4.93e-06	1.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IRS2—osteoporosis	4.92e-06	1.05e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ESR1—osteoporosis	4.91e-06	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6R—osteoporosis	4.84e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LEP—osteoporosis	4.82e-06	1.03e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—osteoporosis	4.77e-06	1.02e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPP1—osteoporosis	4.77e-06	1.02e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—IRS1—osteoporosis	4.76e-06	1.01e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—osteoporosis	4.75e-06	1.01e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ENO1—osteoporosis	4.72e-06	1.01e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—IDH2—osteoporosis	4.71e-06	1e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PSMA5—osteoporosis	4.66e-06	9.93e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PSMA2—osteoporosis	4.66e-06	9.93e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ESR1—osteoporosis	4.6e-06	9.8e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IRS1—osteoporosis	4.59e-06	9.79e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—osteoporosis	4.51e-06	9.61e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—TGFB1—osteoporosis	4.5e-06	9.58e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6R—osteoporosis	4.47e-06	9.53e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	4.43e-06	9.44e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—osteoporosis	4.43e-06	9.44e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—osteoporosis	4.42e-06	9.43e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TGFB1—osteoporosis	4.42e-06	9.42e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—osteoporosis	4.37e-06	9.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ADCY5—osteoporosis	4.36e-06	9.3e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TGFB1—osteoporosis	4.35e-06	9.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6R—osteoporosis	4.31e-06	9.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS2—osteoporosis	4.31e-06	9.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ACP5—osteoporosis	4.31e-06	9.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IRS1—osteoporosis	4.3e-06	9.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IGF1—osteoporosis	4.25e-06	9.07e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPP1—osteoporosis	4.22e-06	9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—osteoporosis	4.22e-06	8.99e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—osteoporosis	4.19e-06	8.94e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—osteoporosis	4.18e-06	8.92e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—osteoporosis	4.18e-06	8.91e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TGFB1—osteoporosis	4.17e-06	8.88e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—osteoporosis	4.16e-06	8.87e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—osteoporosis	4.14e-06	8.82e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ADCY5—osteoporosis	4.09e-06	8.72e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GPX1—osteoporosis	4.08e-06	8.69e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—osteoporosis	4.05e-06	8.64e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TGFB1—osteoporosis	4.04e-06	8.62e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—osteoporosis	4.04e-06	8.61e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6R—osteoporosis	4.04e-06	8.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ESR1—osteoporosis	4.03e-06	8.59e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—osteoporosis	4.02e-06	8.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPI1—osteoporosis	4.01e-06	8.54e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—osteoporosis	3.99e-06	8.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IGF1—osteoporosis	3.98e-06	8.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS2—osteoporosis	3.82e-06	8.14e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—osteoporosis	3.78e-06	8.06e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP19A1—osteoporosis	3.78e-06	8.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—P4HB—osteoporosis	3.77e-06	8.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IRS1—osteoporosis	3.76e-06	8.02e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—osteoporosis	3.76e-06	8.02e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—osteoporosis	3.74e-06	7.96e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—osteoporosis	3.73e-06	7.96e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—osteoporosis	3.7e-06	7.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GAPDH—osteoporosis	3.7e-06	7.88e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—osteoporosis	3.68e-06	7.85e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—osteoporosis	3.67e-06	7.82e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—osteoporosis	3.62e-06	7.73e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RAP1A—osteoporosis	3.6e-06	7.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ESR1—osteoporosis	3.57e-06	7.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6R—osteoporosis	3.54e-06	7.54e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—osteoporosis	3.49e-06	7.43e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—osteoporosis	3.48e-06	7.41e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—osteoporosis	3.47e-06	7.39e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—osteoporosis	3.43e-06	7.31e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—osteoporosis	3.42e-06	7.29e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—osteoporosis	3.42e-06	7.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—osteoporosis	3.41e-06	7.26e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—osteoporosis	3.39e-06	7.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS1—osteoporosis	3.33e-06	7.1e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—osteoporosis	3.33e-06	7.1e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—osteoporosis	3.28e-06	7e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—osteoporosis	3.25e-06	6.93e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—osteoporosis	3.24e-06	6.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—osteoporosis	3.21e-06	6.84e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—osteoporosis	3.16e-06	6.73e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—osteoporosis	3.15e-06	6.71e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—osteoporosis	3.14e-06	6.69e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6R—osteoporosis	3.13e-06	6.67e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADCY5—osteoporosis	3.09e-06	6.58e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—osteoporosis	3.09e-06	6.58e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—osteoporosis	3.08e-06	6.56e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—osteoporosis	3.05e-06	6.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—osteoporosis	3.04e-06	6.49e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—osteoporosis	3.01e-06	6.41e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—osteoporosis	2.99e-06	6.38e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—osteoporosis	2.98e-06	6.36e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—osteoporosis	2.97e-06	6.33e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—osteoporosis	2.96e-06	6.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ENO1—osteoporosis	2.91e-06	6.21e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.87e-06	6.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.87e-06	6.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—osteoporosis	2.84e-06	6.05e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—osteoporosis	2.78e-06	5.93e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—osteoporosis	2.65e-06	5.65e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—osteoporosis	2.64e-06	5.63e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—osteoporosis	2.61e-06	5.57e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—osteoporosis	2.58e-06	5.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—osteoporosis	2.57e-06	5.47e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—osteoporosis	2.56e-06	5.45e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—osteoporosis	2.55e-06	5.44e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—osteoporosis	2.44e-06	5.21e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—osteoporosis	2.44e-06	5.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—osteoporosis	2.39e-06	5.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—osteoporosis	2.39e-06	5.09e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—osteoporosis	2.37e-06	5.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.33e-06	4.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—osteoporosis	2.27e-06	4.84e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—osteoporosis	2.25e-06	4.79e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—osteoporosis	2.16e-06	4.6e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—osteoporosis	2.09e-06	4.47e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—osteoporosis	2.09e-06	4.46e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—osteoporosis	1.99e-06	4.24e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—osteoporosis	1.92e-06	4.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.9e-06	4.05e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—osteoporosis	1.89e-06	4.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—osteoporosis	1.85e-06	3.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—osteoporosis	1.85e-06	3.94e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—osteoporosis	1.8e-06	3.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.75e-06	3.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—osteoporosis	1.57e-06	3.36e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—osteoporosis	1.4e-06	2.98e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—osteoporosis	1.39e-06	2.97e-06	CbGpPWpGaD
